Page 147 - Haematologica May 2022

DA-EPOCH-R in double expressor lymphoma
Aim of the study and statistical analysis
Objectives of the study were assessment of the effect of biological variables (TP53 mutations and BCL2 and MYC translocations) on survival analyses at 2-years in a large cohort of DEL patients consecutively treated with DA-EPOCH-R. Analysis of the cumulative risk of CNS recurrence in the
whole population and PFS and OS impact of different CNS prophylaxis were also evaluated. Fisher’s exact test was per- formed to assess the association between TP53 mutation sta- tus and patients’ clinical characteristics. Statistical analyses were performed using R (version 3.5.0) (detailed in the Online Supplementary Appendix).
Table 1. Clinical characteristics of 122 consecutive diffuse large B-cell lymphoma patients overall and according to rearrangements.
Age, continuous Median (years) third/first quartile Age, categorical
≤60 years old
>60 years old Rearrangements
None DEL-BCL2 DEL-MYC DEL-DH/TH
Ki67 (%)* Median
third/first quartile Sex
Male
Female Cell of origin
GCB Non-GCB Not assessed
Staging I-II
III-IV IPI
0-2
3-5 CNS-IPI
0-1 2-3 4-6
Extranodal site (at risk for CNS)
Yes
No
CNS prophylaxis
None IT MTX IV MTX
Autologous SCT Yes
No
BCL2
N=13
64.0 (55.0; 67.0)
5 (38.5) 8 (61.5)
-
90.0 (85.0; 95.0)
7 (53.8) 6 (46.2)
10 (76.9) 3 (23.1) 0 (0.0)
2 (15.4) 11 (84.6)
4 (30.8) 9 (69.2)
3 (23.1) 5 (38.5) 5 (38.5)
0 (0.0) 13 (100.0)
0 (0.0) 5 (38.5) 8 (61.5)
3 (23.1) 10 (76.9)
MYC
N=9
57.0 (37.0; 61.0)
5 (55.6) 4 (44.4)
HG-BCL N=19
62.0 (57.0; 67.0)
8 (42.1) 11 (57.9 )
Overall N=122
59.0 (49.0; 65.0)
66 (54.1) 56 (45.9)
81 (66.4) 13 (10.7) 9 (7.4) 19 (15.6)
90.0 (75.0; 90.0)
75 (61.5) 47 (38.5)
55 (45.1) 60 (49.2) 7 (5.7)
27 (22.1) 95 (77.9)
55 (45.1) 67 (54.9)
31 (25.4) 61 (50.0) 30 (24.6)
16 (13.1) 106 (86.9)
16 (13.1) 40 (32.8) 66 (54.1)
22 (18.0)
100 (82.0)
DEL N=81
57.0 (46.0; 64.0)
48 (59.3) 33 (40.7)
81 (100)
-
- - 9(100) -
- - - 19(100)
13 (100)
--
--
90.0 (80.0; 90.0)
49 (60.5) 32 (39.5)
22 (27.2) 52 (64.2) 7 (8.6)
18 (22.2) 63 (77.8)
40 (49.4) 41 (50.6)
21 (25.9) 47 (58.0) 13 (16.0)
10 (12.3) 71 (87.7)
12 (14.8) 24 (29.6) 45 (55.6)
12 (14.8)
69 (85.2)
90.0 (81,3; 91.3)
6 (66.7) 3 (33.3)
5 (55.6) 4 (44.4) 0 (0.0)
4 (44.4) 5 (55.6)
6 (66.7) 3 (33.3)
5 (55.6) 2 (22.2) 2 (22.2)
4 (44.4) 5 (55.6)
1 (11.1) 3 (33.3) 5 (55.6)
1 (11.1) 8 (88.9)
75.0 (65.0; 87.5)
13 (68.4) 6 (31.6)
18 (94.7) 1 (5.3) 0 (0.0)
3 (15.8) 16 (84.2)
5 (26.3) 14 (73.7)
2 (10.5) 7 (36.8) 10 (52.6)
2 (10 .5) 17 (89.5)
3 (15.8) 8 (42.1) 8 (42.1)
6 (31.6) 13 (68.4)
DEL: double expressor lymphomas; HG-BCL: high-grade B-cell lymphomas; DH/TH: double-hit/triple-hit; GCB: germinal center lymphomas; Non-GCB: non-germinal center lym- phomas; IPI: International prognostic index; CNS: central nervous system; IT: intrathecal; MTX: methotrexate; IV: intravenous; SCT: stem cell transplantation. *10 missing values, 8 in DEL group and 1 each in DEL/BCL2 and DEL/MYC rearrangements group.
haematologica | 2022; 107(5)
1155